Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 24.04%

Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has an Asset Resilience Ratio of 24.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002262 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥2.18 Billion
≈ $319.44 Million USD Cash + Short-term Investments

Total Assets

CN¥9.08 Billion
≈ $1.33 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Jiangsu Nhwa Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Jiangsu Nhwa Pharmaceutical Co Ltd book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002262 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.18 Billion 24.04%
Total Liquid Assets CN¥2.18 Billion 24.04%

Asset Resilience Insights

  • Good Liquidity Position: Jiangsu Nhwa Pharmaceutical Co Ltd maintains a healthy 24.04% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Nhwa Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Nhwa Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Jiangsu Nhwa Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Jiangsu Nhwa Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 28.12% CN¥2.37 Billion
≈ $347.24 Million
CN¥8.44 Billion
≈ $1.24 Billion
+9.90pp
2023-12-31 18.22% CN¥1.33 Billion
≈ $195.35 Million
CN¥7.33 Billion
≈ $1.07 Billion
-4.18pp
2022-12-31 22.40% CN¥1.45 Billion
≈ $212.47 Million
CN¥6.48 Billion
≈ $948.48 Million
+3.82pp
2021-12-31 18.58% CN¥1.06 Billion
≈ $154.88 Million
CN¥5.70 Billion
≈ $833.68 Million
+0.95pp
2020-12-31 17.63% CN¥837.00 Million
≈ $122.48 Million
CN¥4.75 Billion
≈ $694.85 Million
+15.96pp
2019-12-31 1.67% CN¥70.00 Million
≈ $10.24 Million
CN¥4.20 Billion
≈ $614.81 Million
-10.86pp
2018-12-31 12.53% CN¥505.00 Million
≈ $73.90 Million
CN¥4.03 Billion
≈ $589.74 Million
+2.35pp
2017-12-31 10.18% CN¥336.05 Million
≈ $49.17 Million
CN¥3.30 Billion
≈ $483.12 Million
+6.14pp
2016-12-31 4.03% CN¥120.00 Million
≈ $17.56 Million
CN¥2.97 Billion
≈ $435.32 Million
--
pp = percentage points

About Jiangsu Nhwa Pharmaceutical Co Ltd

SHE:002262 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.33 Billion
CN¥22.77 Billion CNY
Market Cap Rank
#4628 Global
#850 in China
Share Price
CN¥22.42
Change (1 day)
+0.04%
52-Week Range
CN¥20.78 - CN¥28.92
All Time High
CN¥31.19
About

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more